BMY » Topics » BioPharmaceuticals

This excerpt taken from the BMY 8-K filed Oct 22, 2009.

BioPharmaceuticals

 

 

BioPharmaceuticals net sales totaled $4.8 billion in the third quarter of 2009, representing an increase of 6%, or 9% excluding foreign exchange impact, compared to the same period in 2008. U.S. BioPharmaceuticals net sales increased 12% to $3.0 billion in the third quarter of 2009 compared to 2008. International BioPharmaceuticals net sales decreased 2%, or increased 5% excluding foreign exchange impact, to $1.8 billion.

 

   

Sales growth in the third quarter was led by continued sales increases for PLAVIX® (+8%) and strong global sales growth for ABILIFY® (+16%).

 

   

The virology portfolio continues to demonstrate worldwide sales growth, led by BARACLUDE® for hepatitis B (+33%), the Sustiva franchise (+7%) and REYATAZ® for HIV (+5%).

 

   

ORENCIA® and SPRYCEL® grew worldwide 36% and 30%, respectively as compared to the same period in 2008.

 

   

ERBITUX® sales were down 3% compared to the third quarter 2008.

 

   

ONGLYZA® has been launched in the U.S. and Europe and contributed approximately $20 million in sales in the third quarter.

 

 

BioPharmaceuticals realized a 170 basis point increase in gross margin compared to the third quarter of 2008. Key drivers of the improvement were higher biopharmaceutical average price, cost savings, including those related to continuous improvement initiatives, foreign exchange favorability and product mix.

 

 

BioPharmaceuticals pre-tax earnings increased 19% to $1.2 billion in the third quarter of 2009 compared to the same period in 2008. The increase in earnings was driven by increased sales, improved gross margins as well as reductions in marketing, selling and administrative expenses from the company’s continuous improvement initiatives.

 

3


This excerpt taken from the BMY 8-K filed Jul 23, 2009.

BioPharmaceuticals

 

 

BioPharmaceuticals net sales totaled $4.7 billion in the second quarter of 2009, representing an increase of 4%, or 9% excluding foreign exchange impact, compared to the same period in 2008. U.S. BioPharmaceuticals net sales increased 13% to $3.0 billion in the second quarter of 2009 compared to 2008. International BioPharmaceuticals net sales decreased 9%, or increased 4% excluding foreign exchange impact, to $1.7 billion.

 

   

Sales growth in the second quarter was led by continued global sales increases for PLAVIX® (+11%) and strong global sales growth for ABILIFY® (+22%).

 

   

Bristol-Myers Squibb’s virology portfolio, led by BARACLUDE® for hepatitis B (+32%), the Sustiva franchise (+11%) and REYATAZ® for HIV (+2%), continues to demonstrate worldwide sales growth.

 

   

ORENCIA® and SPRYCEL® grew worldwide 40% and 41%, respectively as compared to the same period in 2008.

 

   

ERBITUX® sales were down 12% compared to the first quarter 2008.

 

 

BioPharmaceuticals realized a 410 basis point increase in gross margin compared to the second quarter of 2008. Key drivers of the improvement were cost savings, including those related to productivity initiatives, foreign exchange favorability and product mix.

 

 

BioPharmaceuticals earnings increased 46% to $1.2 billion in the second quarter of 2009 compared to the same period in 2008. The increase in earnings was driven by increased sales, improved gross margins as well as reductions in marketing, selling and administrative expenses from the company’s productivity initiatives.

This excerpt taken from the BMY 10-Q filed Apr 28, 2009.

BioPharmaceuticals

Earnings increased primarily due to increased sales of ABILIFY*, PLAVIX*, the HIV and hepatitis portfolio, SPRYCEL and ORENCIA. The increase in segment income, as a percentage of segment net sales, was primarily due to similar factors discussed in the analysis of consolidated expenses. A more favorable product sales mix, higher average selling prices and realized manufacturing savings from PTI contributed to a reduction of cost of products sold as a percentage of net sales. The results of PTI also contributed to a reduction of marketing, selling and administrative expenses as a percentage of net sales.

This excerpt taken from the BMY 8-K filed Apr 28, 2009.

BioPharmaceuticals

Earnings increased in 2008 primarily due to increased sales of PLAVIX*, ABILIFY*, the HIV and hepatitis portfolio and ORENCIA. The increase in segment income as a percentage of segment net sales in 2008 was primarily due to similar factors discussed in the analysis of consolidated expenses. A more favorable product sales mix, higher average selling prices and realized manufacturing savings from PTI contributed to a reduction of costs of products sold as a percentage of net sales. The results of PTI also contributed to a reduction of marketing, selling and administrative expense as a percentage of net sales.

Earnings increased in 2007 primarily due to increased PLAVIX* sales and strong sales growth of other key products. The increase in segment income as a percentage of segment net sales in 2007 was similar to the reasons discussed above although to a lesser extent as PTI was beginning in 2007.

"BioPharmaceuticals" elsewhere:

AstraZeneca (AZN)
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki